The challenge with existing intravenous mRNA delivery systems has long been their inability to selectively localize therapeutic agents to the pancreas. Most current methods rely on systemic circulation that tends to scatter administered drugs widely throughout various tissues, diminishing efficacy and increasing unwanted off-target effects. The research team at UNLV, led by Professor Chandrabali Bhattacharya, successfully circumvented this limitation by engineering a novel class of lipid nanoparticles, which they have trademarked as ENDO (Endogenous Targeting Lipid Nanoparticles). Unlike conventional nanoparticles that follow non-specific biodistribution patterns, ENDO particles harness the body’s endogenous material transport mechanisms to home in on the pancreas with remarkable specificity.

A key insight driving this technology is the exploitation of Vitamin D receptors found on the surface of certain cells. These receptors, though distributed widely in the body, are present in particular conformation and density on pancreatic cells’ surfaces, making them ideal “coordinates” for nanoparticle targeting. By incorporating vitamin D or similar biologically relevant molecules into the lipid nanoparticle formulation, the research team was able to program these particles to interact selectively with Vitamin D receptors, effectively commandeering the body’s natural transport pathways to direct their cargoes to the pancreas.

This targeted delivery system was shown to achieve a phenomenal selectivity rate of approximately 99 percent for the pancreas following systemic intravenous injection. To put this achievement into perspective, no previous material or delivery vector had demonstrated such a high degree of natural pancreatic tropism upon intravenous administration, marking a decisive milestone in nanomedicine. This breakthrough is not merely a proof-of-concept but represents a scalable and adaptable platform for the systemic administration of nucleic acid-based therapies to an organ notoriously difficult to reach.

The implications of this targeted mRNA delivery technology are immense, particularly for chronic and life-altering conditions such as diabetes. Current insulin therapies require lifelong administration and continuous monitoring, often burdening patients with recurrent costs and variability in glucose control. mRNA therapeutics delivered directly to pancreatic cells could potentially modulate or restore endogenous insulin production, thereby mitigating disease progression. Lead author Ivan Isaac emphasizes that this innovative therapy could slow down or even reverse beta cell loss—the hallmark of diabetes progression—reducing the need for frequent injections and offering patients a significantly improved quality of life.

Beyond diabetes, the ENDO platform holds promise in addressing pancreatic cancer, a disease with notoriously poor prognosis and limited treatment options due to the pancreas’ relative inaccessibility. By enabling precise delivery of mRNA molecules encoding for tumor suppressors or immune modulators, this technology could revolutionize how oncologists approach pancreatic tumors, potentially enhancing therapeutic efficacy while minimizing systemic toxicities associated with chemotherapy or radiation.

The researchers achieved this feat by meticulous reengineering of the lipid nanoparticle composition. Incorporating endogenous molecules such as vitamin D not only improved targeting specificity but also improved biocompatibility and reduced immunogenicity. This endogenous biomimicry enables the nanoparticles to evade rapid clearance by the immune system, prolonging their circulation time and enhancing tissue uptake. Through extensive in vitro and in vivo studies, the team demonstrated the critical role of the Vitamin D receptor-mediated route, confirming that blocking these receptors significantly reduces pancreatic nanoparticle uptake, thereby validating the targeting mechanism.

This accomplishment also marks a critical conceptual advancement by breaking the existing paradigm that liver-targeted delivery is often the default in mRNA therapies due to the organ’s natural propensity to sequester nanoparticles. By devising a strategy to bypass the liver and enrich therapeutic payloads in the pancreas, the research paves the way for expanding mRNA therapeutics beyond hepatic applications to other vital organs that have remained elusive targets until now.

UNLV’s study further underlines the versatile nature of the ENDO system, which the researchers are already customizing for delivery to other challenging tissues such as the brain and heart. These organs similarly pose formidable barriers for drug delivery due to protective anatomical features like the blood-brain barrier and complex vascularization. The researchers believe that by adjusting ligand composition and nanoparticle architecture, this platform could eventually offer unprecedented precision in treating neurodegenerative disorders, cardiovascular diseases, and beyond.

Ivan Isaac, a graduate researcher deeply involved in the development of ENDO, envisions a future where precision nanomedicine fundamentally reshapes therapeutic regimens. Emphasizing safety and patient tolerance, he expects next-generation delivery platforms to reduce immune activation and side effects often associated with RNA vaccines and therapies, thereby broadening the clinical applicability of mRNA technologies. This could herald a new era where treatment regimens become less frequent, less invasive, and more effective.

Commercialization efforts are underway in collaboration with UNLV’s Office of Economic Development, reflecting confidence in the technology’s translational potential. The ability to reliably produce and scale ENDO nanoparticles could prompt rapid adoption in pharmaceutical pipelines, encouraging partnerships aimed at accelerating clinical trials and eventual FDA approval. The team remains committed to advancing this platform from bench to bedside, anticipating that their innovation will serve as a foundational blueprint for precision organ-targeted therapeutics.

Professor Bhattacharya underscores the monumental nature of this achievement, framing it as a foundational stepping stone that can catalyze a paradigm shift in drug delivery science. By bridging molecular biology, chemistry, and nanotechnology, the ENDO system exemplifies the convergence of interdisciplinary research driving forward the future of personalized medicine. The prospect of safer, more effective, and organ-specific therapies no longer seems distant but imminently achievable.

In conclusion, this transformative research signifies a remarkable stride toward overcoming one of the most persistent challenges in drug delivery — the ability to selectively and systemically target therapeutics to specific internal organs. The successful routing of mRNA to the pancreas via endogenous Vitamin D receptor pathways heralds a new dawn in the treatment of pancreatic diseases and opens vast unexplored avenues for mRNA-based interventions that could impact a plethora of medical conditions in the years ahead.

Subject of Research: Cells
Article Title: Reengineering Endogenous Targeting Lipid Nanoparticles (ENDO) for Systemic Delivery of mRNA to Pancreas
News Publication Date: 12-Jun-2025
Web References: https://advanced.onlinelibrary.wiley.com/doi/10.1002/adma.202507657
References: Bhattacharya, C., Isaac, I., Patel, L., Tran, N., Singam, A., Yun, D.S., Guha, P., Park, S. (2025). Reengineering Endogenous Targeting Lipid Nanoparticles (ENDO) for Systemic Delivery of mRNA to Pancreas. Advanced Materials.
Keywords: Autoimmune disorders, Type 1 diabetes, Type 2 diabetes, Insulin, Diabetes, Diseases and disorders, Pancreatic cancer, Pancreatitis

Traditionally, administering drugs through the bloodstream resulted in them predominantly being processed by the liver, often leading to unwanted side effects and reduced therapeutic efficacy. The breakthrough presented by Dr. Riccardo Rampado and his team, including the visionary Prof. Dan Peer, addresses these limitations by allowing for the direct delivery of mRNA-based therapeutics to specific areas where they are needed most. By modifying the composition of the lipid nanoparticles, they have demonstrated that it is possible to guide the mRNA directly to the targeted cells in the intestines, thereby minimizing systemic exposure and potential toxicity to the liver.

One of the major challenges in drug delivery has been the fact that nearly all substances introduced into the bloodstream end up in the liver. As noted by Prof. Peer, this poses two significant hurdles: the risk of liver toxicity from drugs meant for other tissues and the need to ensure that those drugs do not become trapped in the liver. The researchers discovered that by adjusting the lipid composition of the nanoparticles, they could influence their trajectory in the bloodstream, effectively dictating where the drugs would accumulate.

In their study, the team encapsulated the anti-inflammatory protein interleukin-10 into mRNA within lipid nanoparticles specifically designed for this purpose. Rather than using conventional formulations typically used in mRNA vaccines, they created a customized composition that significantly improved delivery efficiency to the intestines. This method allowed researchers to tackle inflammatory diseases directly within the digestive tract, providing a powerful new avenue for therapeutic intervention.

The implications of this research are profound. By not only delivering mRNA encoding an anti-inflammatory agent but also converting the immune cells in the intestines into factories that produce interleukin-10, the study showcases the potential for self-sustaining treatments for chronic inflammatory conditions. While this proof-of-concept work represents a significant leap forward, it also opens the door to further exploration of how varying the nanoparticle composition might allow for the delivery of a broader spectrum of RNA-based medications to diverse organs within the body.

Delving deeper into the science, lipid nanoparticles function by mimicking biological membranes, allowing them to traverse cellular barriers more effectively. In the context of this research, the team increased the ratio of phosphatidylcholine, a critical phospholipid component found in cell membranes, from the typical 10% used in vaccines to 30%. This adjustment was pivotal; it resulted in the nanoparticles exhibiting unique behavior in the bloodstream, akin to oil floating on water. Such behavior is crucial for targeting the nanoparticles to specific tissues, allowing for unprecedented precision in drug delivery.

Prof. Peer further elaborated on the significance of this lipid composition modification, explaining that it has a scientific basis rather than being a mere trial-and-error approach. The chosen ratio closely resembles the natural biological membranes of intestinal cells, enhancing the likelihood of successful uptake and therapeutic action. This understanding positions the research as not only a milestone in drug delivery but also as a potential template for future innovations aimed at refined therapeutic strategies.

The possibilities this research unlocks for the treatment of not only inflammatory bowel diseases but also other medical conditions are vast. The adaptability of the nanoparticle formulation could lead to targeted therapies for organs beyond the intestines, such as the pancreas, or even the brain, which have historically proven difficult to reach with conventional treatments. The researchers plan to explore these options as they continue to push the boundaries of what’s possible in drug delivery systems.

As this research gains recognition, it highlights the importance of interdisciplinary collaboration in advancing the frontiers of medicine. The expertise of the Tel Aviv University team, combining elements of biochemistry, materials science, and pharmacology, has led to innovative breakthroughs that could alter the course of treatment for millions suffering from chronic diseases. The translation of these scientific advancements into clinical practice will hinge on further studies, but the initial results are promising and indicative of a new era in targeted drug delivery.

Furthermore, the implications extend beyond just the immediate treatment of gastrointestinal disorders; this work signifies a paradigm shift toward more personalized, effective therapies that can be tailored to individual patient needs. By mitigating off-target effects and leveraging the body’s natural capabilities, the scientific community is one step closer to integrating advanced RNA-based therapies into mainstream medical practice.

In conclusion, the groundbreaking work emerging from Tel Aviv University illustrates the transformative potential of lipid nanoparticle technology in drug delivery systems. By harnessing the power of mRNA and precision targeting, researchers are paving the way for more effective treatments for some of the most challenging health conditions faced today. As they continue to refine this technology, the prospect of achieving better patient outcomes through innovative therapies becomes increasingly tangible.

Subject of Research: Targeted drug delivery using lipid nanoparticles for mRNA therapeutics
Article Title: Breakthrough in Targeted Drug Delivery: Tel Aviv University Researchers Successfully Transport mRNA to the Intestines
News Publication Date: October 2023
Web References: Advanced Science Journal
References: Advanced Science
Image Credits: Tel Aviv University

Keywords: lipid nanoparticles, drug delivery, inflammatory diseases, mRNA therapeutics, interleukin-10, targeted therapy, Crohn’s disease, colitis, phosphatidylcholine, medical research, Tel Aviv University, Prof. Dan Peer